Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 781 to 795 of 2208 results for guidelines

  1. Diabetes: lipid-lowering therapies for secondary prevention of CVD (IND276)

    This indicator covers the percentage of patients with diabetes and a history of cardiovascular disease (excluding a history of haemorrhagic stroke) who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  2. EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (HTG611)

    Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules.

  3. Experience: GP services (IND288)

    This indicator covers patient experiences of GP services. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  4. Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (TA1040)

    Evidence-based recommendations on olaparib (Lynparza) for BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy in adults.

  5. Tocilizumab for treating giant cell arteritis (TA518)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.

  6. Experience: A&E (IND291)

    This indicator covers patient experiences of A&E. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  7. Experience: hospital (IND290)

    This indicator covers patient experiences of hospital. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  8. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.

  9. Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (HTG467)

    Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical abnormalities in people having colposcopy.

  10. Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)

    NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .

  11. Dexcom G6 for real-time continuous glucose monitoring (MIB233)

    NICE has developed a medtech innovation briefing (MIB) on Dexcom G6 for real-time continuous glucose monitoring .

  12. Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers (HTG355)

    Evidence-based recommendations on Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers.

  13. Hip fracture: surgery on the day or day after admission (IND14)

    This indicator covers the proportion of people with hip fracture, who receive surgery on the day of, or the day after, admission. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG21

  14. Hypertension: confirming diagnosis with HBPM or ABPM (IND115)

    This indicator covers the percentage of patients with a new diagnosis of hypertension (diagnosed on or after 1 April 2014) which has been confirmed by ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) in the 3 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM66